Impaired Regulation by IL-35 in Systemic Sclerosis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310567 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rubén Osuna-Gómez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Diseases, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: Interleukin-17, Scleroderma, Systemic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study investigated the role of IL-35 in systemic sclerosis (SSc) patients, focusing on CD4+ T cell response and immunomodulatory cytokine production. By comparing the cytokine levels in healthy donors (HD) and SSc patients using ELISAs, we found a significantly lower plasma IL-35 concentration in the SSc patients (52.1 ± 5.6 vs. 143 ± 11.1, p < 0.001). Notably, the IL-35 levels showed a negative correlation with TGF-β (p < 0.001) and IL-17 (p = 0.04). Assessing the IL-35R expression across cell types in the SSc patients and HDs via flow cytometry, we found higher levels on monocytes (40.7 + 5.7 vs. 20.3 ± 1.9, p < 0.001) and lower levels on CD8+ T cells (61.8 ± 9.2 vs. 83.4 ± 0.8, p < 0.05) in the SSc patients. The addition of recombinant IL-35 to stimulated peripheral blood mononuclear cells reduced the IL-17+CD4+ T cell percentage (9.0 ± 1.5 vs. 4.8 ± 0.7, p < 0.05) and increased the IL-35+CD4+ T percentage (4.1 ± 2.3 vs. 10.2 ± 0.8, p < 0.001). In a Treg:Tresponder cell Sco-culture assay with HD and SSc samples, rIL35 decreased the cell proliferation and levels of IL-17A (178.2 ± 30.5 pg/mL vs. 37.4 ± 6.4 pg/mL, p < 0.001) and TGF-β (4194 ± 777 pg/mL vs. 2413 ± 608 pg/mL, p < 0.01). Furthermore, we observed a positive correlation between the modified Rodnan skin score (mRSS) and TGF-β (p < 0.001), while there was a negative correlation between mRSS and IL-35 (p = 0.004). Interestingly, higher levels of plasmatic IL-35 were detected in individuals with limited disease compared to those with diffuse disease (60.1 ± 8.0 vs. 832.3 ± 4.1, p < 0.05). These findings suggest that IL-35 exhibits anti-inflammatory properties in SSc and it may serve as a marker for disease severity and a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammatory Diseases, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain.
- Department of Rheumatology and Systemic Autoimmune Diseases, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
- Precigen, Inc., Germantown, MD 20876, USA.
ORCID-Profile: Rubén Osuna-Gómez, Ivan Castellví, Maria Mulet, Mª Àngels Ortiz, Silvia Vidal
Zitieren
APA
Osuna-Gómez, R., Castellví, I., Mulet, M., Ortiz, M. À., Brough, D. E., Sabzevari, H., Semnani, R. T., & Vidal, S. (2023). Impaired Regulation by IL-35 in Systemic Sclerosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310567
Vancouver
Osuna-Gómez R, Castellví I, Mulet M, Ortiz MÀ, Brough DE, Sabzevari H, et al. Impaired Regulation by IL-35 in Systemic Sclerosis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310567
BibTeX
@article{OsunaGmez2023,
author = {Osuna-Gómez, Rubén and Castellví, Ivan and Mulet, Maria and Ortiz, Mª Àngels and Brough, Douglas E and Sabzevari, Helen and Semnani, Roshanak T and Vidal, Silvia},
title = {Impaired Regulation by IL-35 in Systemic Sclerosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310567}
}
EUVIMED